. Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. Alzheimers Dement. 2010 Sep;6(5):367-77. PubMed.


Please login to recommend the paper.


Comments on this Paper

No Available Comments

Make a Comment

To make a comment you must login or register.